A 31-year-old woman with recently diagnosed relapsing-remitting MS presents for discussion of disease-modifying therapy. Her vital signs are stable (BP 118/76, HR 82, RR 16, Temp 37.0°C, SpO2 98% on room air). Brain MRI reveals 2 T2 hyperintense lesions and 1 gadolinium-enhancing lesion. CSF oligoclonal bands are positive. She has experienced one clinical relapse in the past year with residual mild lower extremity weakness. She denies recent infections. Which therapeutic approach is most appropriate?
- A)Plasmapheresis
- B)First-line disease-modifying therapy (interferon-beta or glatiramer acetate)GABARITO
- C)Immunoglobulin infusion
- D)High-dose corticosteroids for acute relapse only
- E)No treatment; monitor with clinical observation alone
Explicação
Current MS treatment guidelines recommend initiating disease-modifying therapy (DMT) at diagnosis for relapsing MS. First-line agents include interferon-beta and glatiramer acetate. Early treatment slows disease progression and reduces relapse rate, even with ... Ver explicação completa e trilha adaptativa →